pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

193 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints874BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7341Rare Disease1825Cardiology1672Immunology1454Hematology1301Vaccines1173Pulmonology1084Psychiatry & CNS
  • Deepfake videos of doctors threaten trust in telehealth and digital care
    A patient recently presented a video that appeared to show her physician in a white coat, recommending an over‑the‑counter hormone supplement and disparaging standard treatments. The doctor confirm…
    STAT · 1mo agoNegative↗ source
  • Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and Biogen
    Lyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
    Endpoints · 1mo agoPositive↗ source
← prev
page 6 of 8
next →
fda recalls67
fda medwatch60
fda press38
858
Ophthalmology491
Pain468
Endocrinology & Metabolism465
Infectious Disease437
Cyclospora infections hit record high in 2026, Michigan officials suspect lettuce as source
Infections caused by the parasite Cyclospora have surged to a record level in 2026, with more than 30 states reporting cases that now exceed the previous U.S. high of about 4,700 set in 2019. The…
STAT · 1mo agoNegative↗ source
  • Ohio launches $30M Life Science Training Center to boost biomanufacturing workforce
    Ohio’s JobsOhio agency and the Ohio Life Sciences Association announced a public-private training center backed by up to $30 million. The center is intended to create a statewide pipeline of operat…
    Fierce Biotech · 1mo agoPositive↗ source
  • ARPA-H awards $160 M to accelerate bespoke gene‑editing therapies for rare diseases
    ARPA-H announced a $160 million, five‑year investment through its THRIVE program to speed the development of personalized gene‑editing treatments for rare genetic conditions. The awardees include…
    BioPharma Dive · 1mo agoNeutral↗ source
  • RFK Jr. moves to compile list of Covid-19 vaccine injuries to streamline compensation claims
    Health secretary Robert F. Kennedy Jr. announced plans to create a list of injuries that would be presumed caused by Covid-19 vaccines. The list would allow individuals who suffer from those condi…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Oberland invests up to $400M in MeiraGTx eye gene‑therapy pipeline
    Oberland Capital Management announced a financing package that could total $400 million to support MeiraGTx's development of gene therapies for inherited eye disorders. The arrangement includes up…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Anthropic CEO says AI’s biotech breakthrough may still be a decade away despite current hype
    In a recent on‑stage conversation, Matthew Herper interviewed Dario Amodei, the CEO and co‑founder of Anthropic, about the role of artificial intelligence in biotechnology. The discussion took plac…
    STAT · 2mo agoNeutral↗ source
  • ACA enrollment falls sharply, with Ohio and Oklahoma each losing about a third of participants
    New federal data shows steep drops in Affordable Care Act enrollment across the United States, with Ohio and Oklahoma each losing nearly one‑third of their participants. Overall, about 2.6 million…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Roche’s divarasib shows survival benefit over Amgen and BMS drugs in KRAS G12C lung cancer trial
    Roche reported that its experimental KRAS G12C inhibitor divarasib extended overall survival and progression‑free survival in a Phase 3 head‑to‑head study against Amgen’s Lumakra and Bristol Myers…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • FDA approves Viridian's Lumvoa, positioning it against Amgen's Tepezza in thyroid eye disease
    The Food and Drug Administration has granted approval for Viridian Therapeutics' drug Lumvoa to treat thyroid eye disease, an autoimmune condition that can cause eye pain, bulging and vision proble…
    BioPharma Dive · 2mo agoApprovalPositive↗ source
  • Biotech firms raise record funds in 2026, with $2.1 bn round for Isomorphic Labs
    After a few slow years, the biotech financing landscape is showing signs of recovery, though investors remain cautious about where they place capital. A recent PharmaVoice reader poll found that 2…
    BioPharma Dive · 2mo agoDealNeutral↗ source
  • Biotech sector eyes key clinical trial readouts in H2 2026 across cancer, Alzheimer’s and autoimmune diseases
    The first half of 2026 saw a surge in biotech activity, with record‑high deal flow, several large IPOs and a regulatory environment that appears to be stabilising after a period of uncertainty. An…
    BioPharma Dive · 2mo agoNeutral↗ source
  • STAT readers split on spelling of "health care" as industry leans toward single word
    STAT recently asked its audience whether to write the term as two words or one. Roughly 60% of respondents favored one spelling over the other. The discussion highlights a subtle but growing trend…
    STAT · 2mo agoNeutral↗ source
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 2mo agoDealNeutral↗ source
  • UniQure plans to file Huntington’s disease gene therapy with FDA after leadership shift eases data requirements
    UniQure, a Dutch biotech, announced it will seek FDA approval for its gene therapy targeting Huntington’s disease later this summer. The company said FDA staff indicated that three years of data f…
    BioPharma Dive · 2mo agoRegulatoryNeutral↗ source
  • 73-year-old woman begins medical residency, says she's all in
    In a recent First Opinion podcast, Dawn Zuidgeest-Craft, who is nearly 73, shared her decision to start a medical residency after completing medical school in her early seventies. The interview was…
    STAT · 2mo agoPositive↗ source
  • Rapport Therapeutics says it is ready to launch its seizure drug independently
    In a recent interview, CEO Abe Ceesay explained that Rapport Therapeutics has assembled an investor syndicate and feels fully prepared to bring its seizure drug to market on its own. Founded in 20…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trial
    Novartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Long Covid research faces funding cut as NIH terminates grant, highlighting political neglect
    Steven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeli…
    STAT · 2mo agoNegative↗ source
  • AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight loss
    AstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Ethyreal Bio raises $101M to develop antibody targeting Graves disease and thyroid eye disease
    Ethyreal Bio, a Cambridge-based biotech that has just emerged from stealth mode, announced it has closed a $101 million financing round to advance its lead candidate. The company’s candidate, a mo…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease
    Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
    Endpoints · 2mo agoDealPositive↗ source
  • Biopharma CEOs see soaring compensation, new analysis to be discussed live
    Endpoints News released the first installment of its annual biopharma compensation project, breaking down the pay of the industry’s highest-earning CEOs. The company will host a Post-Hoc Live web…
    Endpoints · 3mo agoNeutral↗ source
  • Lilly’s retatrutide data at ADA 2026 underscores its lead in obesity drug market
    The American Diabetes Association’s 2026 meeting highlighted a wave of new weight‑loss drug data as companies vie for a slice of a market dominated by Eli Lilly and Novo Nordisk. Lilly presented r…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source